Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs mainly in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. Co.'s product candidate, CAPLYTA™ (lumateperone) has been approved for the treatment of schizophrenia in adults. Co. is developing ITI-1284, an oral disintegrating tablet for sublingual administration for the treatment of behavioral disturbances in patients with dementia and dementia-related psychosis and for the treatment of certain depressive disorders in the elderly. We show 43 historical shares outstanding datapoints in our ITCI shares outstanding history coverage, used to compute ITCI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ITCI market cap history over the course of time is important for investors
interested in comparing ITCI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ITCI versus a peer is one thing; comparing
ITCI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ITCI can fluctuate over the course of history.
With this page we aim to empower investors researching ITCI by allowing them to research the ITCI market cap history. |
Free ITCI Email Alerts:
Video: The Importance of Market Cap
